About us

Founded in 2015 by two scientists, Géraldine Le Duc and Pr Olivier Tillement, NH TherAguix is a French biotechnology company based in Grenoble. NH TherAguix has developed an innovative theranostic nanodrug called AGuIX® that allows to fight more efficiently against all forms of cancer. 
Thanks to a €13M fund raising in 2019 (BPI, Innobio, Omnes, Arbevel, Supernova), NH THerAguix was able to launch a promising portfolio of clinical trials.